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Interleukin-1a (IL-1a) is a potent proinﬂammatory cytokine constitutively expressed by keratinocytes, which also
synthesize a specific inhibitor of IL-1 activity, intracellular IL-1 receptor antagonist (IL-1ra). Although homeostatic
regulation of the IL-1 system in keratinocytes has long been suspected, there is currently little evidence for this. To
explore this issue, the PAM212 murine keratinocyte cell line was exposed to increasing concentrations of either IL-
1a or IL-1ra and the opposing ligand was assessed by ELISA. Release of IL-1ra was induced following stimulation
by murine IL-1a in a concentration-dependent manner and, conversely, IL-1ra stimulation increased IL-1a release.
To determine whether a similar homeostatic circuit operates in vivo, epidermis from transgenic mice in which
overexpression of IL-1a or IL-1ra was targeted to keratinocytes was analyzed. Epidermal sheets derived from IL-1a
transgenic mice released eight times more IL-1ra than those from wild-type mice following ex vivo culture and
similarly, IL-1a release was increased 3–4-fold in epidermal sheets derived from IL-1ra transgenic epidermis, Use of
specific neutralizing antibodies against type I and type II IL-1 receptors indicated that the counter-regulation
mechanism is mediated extracellularly through the type I IL-1 receptor alone. Taken together, these observations
provide the ﬁrst demonstration of mutual counter-regulation of IL-1 receptor ligands in keratinocytes.
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Interleukin-1 (IL-1) is a pleiotropic cytokine and primary
mediator of cutaneous inflammation (Kupper, 1990; Dinar-
ello, 1996). All biological effects of IL-1 are mediated by two
IL-1 receptor ligands, IL-1a and IL-1b, and can be specif-
ically antagonized by a third ligand, IL-1 receptor antagonist
(IL-1ra), all of which lie in a 430 kb region of chromosome 2
in humans (Nicklin et al, 1994). Both IL-1a and IL-1b are
synthesized as 31 kDa molecules lacking signal peptides,
and whereas IL-1a remains primarily intracellular in its pre-
cursor form, IL-1b is predominantly secreted, following
cleavage to a 17 kDa molecule by the cysteine protease
caspase-1 at the cell surface (Singer et al, 1995). Unlike IL-
1b, the 31 kDa form of IL-1a has full biological activity.
IL-1ra exists in four isoforms, one containing a signal
peptide and predominantly released from monocytes,
whereas the other three lack a leader sequence and are
found within keratinocytes and other human epithelial cells
(Arend and Guthridge, 2000). IL-1a, IL-1b, and IL-1ra exert
their effects through interaction with two specific cell sur-
face receptors. The type I IL-1 receptor (IL-1RI) is an 80 kDa
transmembrane molecule with a signal transducing cyto-
plasmic domain, through which all IL-1-mediated responses
are relayed (Sims et al, 1989). Thus, IL-1RI-deficient mice
fail to respond to IL-1 and display reduced inflammatory
responses (Labow et al, 1997). The type II IL-1 receptor (IL-
1RII) is a smaller molecule (68 kDa) with a truncated cyto-
plasmic domain, which functions as a non-signalling decoy
target for IL-1 receptor ligands (McMahan et al, 1991; Col-
otta et al, 1993). Both IL-1 receptors can be cleaved from
the cell surface, although soluble-type II IL-1 receptor is the
predominant shed form in vivo (Arend et al, 1994).
The epidermis is physiologically unique in being the only
organ in the body to store prodigious quantities of pre-
formed IL-1a (Kupper, 1990) and keratinocytes have been
shown to synthesize both IL-1a and -1b molecules in vitro
(Kupper et al, 1986), in addition to both IL-1 receptors
(Groves et al, 1994). Release of keratinocyte-derived IL-1a
is sufficient to trigger cutaneous inflammation in human
(Camp et al, 1990; Groves et al, 1992) and murine (Groves
et al, 1995b) skin through the induction of secondary
cytokines such as IL-8 and upregulation of endothelial
adhesion molecules. Presumably, in order to control the
potentially harmful effects of excessive IL-1a release in the
epidermis, significant quantities of intracellular IL-1ra (icIL-
1ra) are detectable in keratinocytes (Bigler et al, 1992;
Gabay et al, 1997). In addition to quenching excessive IL-1a
activity, type 1 icIL-1ra may contribute to the inhibition of IL-
1 responses by destabilizing messenger RNA (mRNA) of
some IL-1 inducible genes such as gro-a (Watson et al,
1995) and inhibiting IL-1 signal transduction mediators
(Garat and Arend, 2003). Moreover, activation of keratin-
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ocytes by mitogens or interferon-g results in marked up-
regulation of IL-1RII in vitro and release from the cell sur-
face, adding a further level of control to IL-1 within the
epidermis (Groves et al, 1995a).
Perturbation of the tightly regulated cutaneous IL-1 net-
work can result in profound inflammatory changes in vivo.
For example, transgenic mice that overexpress IL-1a under
the control of a keratin-14 (K14) promoter display a pheno-
type characterized by spontaneous focal inflammatory skin
lesions (Groves et al, 1995b). Further, crossing such animals
with mice that overexpress type-1 IL-1 receptor on keratin-
ocytes results in a significantly more severe phenotype than
that seen in the IL-1a transgenic mice alone (Groves et al,
1996). In contrast, mice that overexpress IL-1RII in basal
keratinocytes display a marked reduction in cutaneous in-
flammatory responses (Rauschmayr et al, 1997). Addition-
ally, alterations in the balance of IL-1 molecules have been
shown in the human epidermis from individuals with inflam-
matory skin diseases such as psoriasis, where IL-1a is
reduced (Cooper et al, 1990) and IL-1ra is increased (Ham-
merberg et al, 1992) and in atopic dermatitis (Terui et al,
1998).
The numerous anti-IL-1 molecules present in the epider-
mis (three isoforms of icIL-1ra, cell surface, and shed type-2
IL-1 receptor) suggest that tightly coordinated regulation of
IL-1 activity is essential in the cutaneous microenvironment
(Kupper and Groves, 1995). Although counter-regulation of
the IL-1 system has long been suspected, formal evidence
for this is lacking. In this study, a murine keratinocyte line
and mice overexpressing either IL-1a or secreted IL-1ra
(sIL-1ra) in basal keratinocytes were used to assess wheth-
er homeostatic mechanisms operate both in vitro and in vivo
in the epidermis.
Results
Homeostatic regulation of IL-1a and IL-1ra release by
murine keratinocytes in vitro We initially exposed cells of
the PAM212 keratinocyte line to increasing concentrations
of recombinant murine IL-1a (rmIL-1a) for 24 h, prior to
analysis of supernatants for total IL-1ra immunoreactivity. In
the absence of IL-1a, PAM212 cells released negligible
quantities of IL-1ra, but this rose in a concentration-de-
pendent manner to 1924  97 pg per mL following expo-
sure to 10 ng per mL IL-1a (Fig 1a).
Following exposure to increasing concentrations (0.03–3
ng per mL) of recombinant IL-1ra, release of IL-1a from
PAM212 cells increased from 529  69 to 1043  57 pg per
mL (Fig 1b). The constitutive release of IL-1a by PAM212 cells
is in agreement with previous studies (Miyazaki et al, 2000)
and the increased release of IL-1a and IL-1ra did not occur
as a consequence of cell death as no increases in supernat-
ant lactate dehydrogenase (LDH) activity were observed in
parallel experiments (data not shown). Moreover, separate
experiments revealed no interference between IL-1a and IL-
1ra in their respective ELISA assays (data not shown).
Counter-regulation of IL-1a and IL-1ra release from ep-
idermis of transgenic mice that overexpress IL-1 family
molecules in vivo To extend the in vitro data, epidermal
sheets were prepared from ears of mice derived from lines
overexpressing either IL-1a (IL-1.2) or sIL-1ra (RA1 and
RA10), in addition to wild-type animals (FVB strain). Homo-
genates were prepared and cytokine content was analyzed
by ELISA. Epidermis from line IL-1.2 displayed levels of IL-
1a approximately 4-fold higher than wild-type (FVB) litter-
mates (21.2  2.3 ng per mg total protein vs 5.5  0.4 ng
per mg, respectively) (Table I). IL-1a levels were unchanged
from wild-type levels in both IL-1ra lines. Similarly, IL-1ra
concentrations were 3-fold higher than FVB mice in one line
overexpressing the secreted keratinocyte isoform, sIL-1ra
(RA1), and increased over 4-fold in line RA10 (67.1  3.3 ng
Figure1
Keratinocytes respond to increasing concentrations of interleukin
(IL)-1a or IL-1 receptor antagonist (IL-1ra) by upregulating release
of the opposing ligand in a concentration-dependent manner.
PAM212 cells were exposed to recombinant murine IL-1a (rmIL-1a) (a)
or rmIL-1ra (b) for 24 h, prior to collection of supernatant and subse-
quent ELISA for mIL-1ra (a) or IL-1a (b). Data represent the mean and
SEM values for each treatment across three replicate experiments.
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per mg total protein vs 194.8  3.6 and 284.7  15.0 ng per
mg, respectively), whereas no differences were observed in
the IL-1.2 line, as expected. Although the ELISA protocol
used did not distinguish between the two IL-1ra isoforms,
reverse transcription polymerase chain reaction (RT-PCR)
analysis of FVB and RA10 epidermal sheets confirmed that
the increase in total IL-1ra protein was derived from a sub-
stantial upregulation of sIL-1ra mRNA (data not shown). The
approximate 10-fold excess of IL-1ra over IL-1a in epider-
mal homogenates from wild-type mice is in agreement
with previous studies analyzing this ratio in keratinocytes
(Kutsch et al, 1993). These data indicate that transgenic
overexpression of IL-1a or IL-1ra in keratinocytes does
not affect the total content of the opposing molecule in the
epidermis.
We were next interested in determining whether trans-
genic overexpression of IL-1a or sIL-1ra had any effect on
release, as opposed to storage, of the opposing molecule.
Thus, epidermal sheets were prepared from transgenic and
wild-type mouse ears and placed in organ culture for 24 h,
prior to determination of supernatant IL-1a or IL-1ra. As
expected, a large increase in IL-1a release was observed
from epidermis derived from IL-1.2 mice compared with
wild-type littermates (16-fold; 2733  177 vs 164  29 pg
per mL), consistent with the upregulation seen in the ho-
mogenates. Moreover, significant increases in epidermal IL-
1a release were also observed in supernatants from epi-
dermal sheets prepared from both RA1 (3-fold; 530  120
pg per mL; po0.01) and RA10 (4-fold; 678  35 pg per mL;
po0.01) lines (Fig 2a). Addition of neutralizing antibody
against IL-1ra to the organ culture medium at the onset
of incubation significantly reduced IL-1a release from
RA10 epidermal sheets (570  42 to 224  9 pg per mL,
po0.001), suggesting that IL-1ra was acting extracellularly
(Fig 2b). Addition of isotype-matched control antibody was
without effect.
In epidermal sheets derived from sIL-1ra transgenic
mice, supernatant IL-1ra levels were markedly increased in
both RA1 and RA10 lines (RA1: 9131  396 pg per mL;
RA10: 23,060  450 pg per mL; FVB: 611  19 pg per mL).
More surprisingly however, an 8-fold increase in IL-1ra re-
lease from IL-1.2 epidermal sheets was also observed
(5006  140 pg per mL; po0.001, Fig 3a). Addition of a
neutralizing antibody against IL-1RI to the organ culture
decreased supernatant IL-1ra levels from 5827  89 pg per
mL in IL-1.2 sheets to 810  66 pg per mL (po0.001, Fig
3b), again suggesting that the IL-1 was acting extra-
cellularly, whereas isotype control antibody was without
effect. To investigate the relative contributions of IL-1ra
isoforms to the increase in IL-1ra release from the IL-1.2
epidermal sheets, RT-PCR experiments were performed on
ear tissue using specific primers to differentiate icIL-1ra and
sIL-1ra transcripts. Although icIL-1ra was found to be the
predominant isoform, in agreement with previous studies
Table I. Analysis of epidermal IL-1a and IL-1ra content in IL-1a
and IL-1ra transgenic micea
Line
IL-1a
(ng per mg total protein)
IL-1ra
(ng per mg total protein)
FVB 5.5  0.4 67.1  3.3
IL-1.2 21.2  2.3 62.7  3.6
RA1 4.1  0.5 194.8  3.6
RA10 4.5  0.5 284.7  15.0
IL, interleukin; IL-1ra, IL-1 receptor antagonist.
aEpidermal homogenates were prepared from the ears of normal, IL-1a
(IL-1.2), and sIL-1ra (RA1 and RA10) transgenic lines, as described and
analyzed by ELISA for IL-1a or IL-1ra protein. Data represent mean
 SEM (n¼ 3).
Figure2
Counter-regulation of interleukin (IL)-1a release in mice transgenic
for secreted interleukin-1 receptor antagonist (sIL-1ra). (a) Epider-
mal sheets prepared from three different lines of transgenic mice were
subjected to 24 h organ culture and supernatants subsequently as-
sayed by ELISA for murine IL-1a (mIL-1a), as described. po0.01 rel-
ative to FVB line; po0.001 relative to FVB line. (b) Epidermal sheets
from RA10 (keratin-14–IL-1ra transgenic) mice were co-incubated with
either a neutralizing antibody against mIL-1ra or an irrelevant control
antibody (CD45) and supernatants subsequently assayed for IL-1a by
ELISA. Data represent the mean and SEM values for each treatment
across three replicate experiments. po0.001.
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(La et al, 1999), there was no significant difference in tran-
scription of this molecule between wild-type and IL-1.2
animals, whereas levels of sIL-1ra mRNA increased
179%  13% between the two lines (data not shown).
Responses to changes in extracellular IL-1a and IL-1ra
concentrations in keratinocytes are mediated through
IL-1RI Having shown counter-regulation of IL-1 receptor
ligands in keratinocytes, the mechanism of control was in-
vestigated by using blocking IL-1R antibodies. PAM212
cells were incubated with 3 ng per mL of either IL-1a or IL-
1ra in the presence or absence of monoclonal neutralizing
antibodies against either mIL-1RI or mIL-1RII for 24 h prior
to ELISA analysis of clarified supernatants. In both cases,
the increases observed with the IL-1 receptor ligands were
completely abrogated in the presence of anti-IL-1RI anti-
body (790  8 to 535  19 pg per mL IL-1a and 1001  46
to 361  41 pg per mL IL-1ra), whereas co-incubation with
anti-IL-1RII antibody was without effect (Fig 4).
Exposure of keratinocytes to soluble IL-1 receptor (sIL-
1R) results in a concentration-dependent increase in IL-
1a release in vitro Finally, to establish whether manipula-
tion of IL-1RI availability would affect the epidermal IL-1
counter-regulation, PAM212 keratinocytes were incubated
overnight at 371C in the presence of increasing concentra-
tions of recombinant human sIL-1RI, a potent pharmaco-
logical IL-1 inhibitor, and supernatants subsequently
analyzed by ELISA for IL-1a. Supernatant IL-1a concentra-
tions increased in a concentration-dependent manner from
230  33 to 500  47 pg per mL in the presence of 100 ng
per mL sIL-1RI (Fig 5). IL-1a/IL-1R complexes were shown
not to interfere with the detection of IL-1a in the ELISA (data
not shown).
Discussion
We describe the counter-regulation of IL-1a and IL-1ra in
murine keratinocytes, evidenced by increases in IL-1a and
IL-1ra release following addition of the opposing ligand,
both in vitro and in an ex vivo organ culture model using
epidermal sheets derived from mice that overexpress
epidermal sIL-1ra and IL-1a. The complex autoregulatory
loops involving released forms of IL-1a and -1b, sIL-1ra, and
IL-1 receptors have been extensively studied in leukocytes.
For example, binding of IL-1a to IL-1RI results in induction
of bio-active IL-1b (Dinarello et al, 1987; Manson et al, 1989)
and sIL-1ra (Jenkins and Arend, 1993), whereas sIL-1ra in-
hibits both the activity and synthesis of IL-1a and -1b in
monocytes (Granowitz et al, 1992). Incubation of peritoneal
macrophages with sIL-1RI has been reported to induce a
significant release of IL-1a in a concentration-dependent
manner, consistent with these data and the same study re-
ported a rapid and substantial systemic release of IL-1a
following intra-peritoneal injection of sIL-1RI in mice (Netea
et al, 1999).
In cutaneous cells, icIL-1ra has been shown to be ele-
vated in lysates from human dermal fibroblasts over-
expressing proIL-1a, although in the converse experiment,
fibroblasts transduced to overexpress icIL-1ra failed to
show any increases in IL-1a production (Higgins et al, 1999).
Additionally, primary murine keratinocytes have been shown
to upregulate icIL-1ra mRNA production following IL-1a ex-
posure in a time- and concentration-dependent manner (La
et al, 1999) and transcription factor binding sites on the icIL-
1ra promoter responsible for this increase, including AP-1,
have been identified (La and Fischer, 2001; La et al, 2002).
Our findings extend these observations by the demonstra-
tion of a concentration-dependent induction of IL-1ra pro-
tein release by IL-1a and our observation that IL-1a release
Figure 3
Counter-regulation of interleukin-1 receptor antagonist (IL-1ra) re-
lease in mice transgenic for IL-1a. (a) Epidermal sheets prepared
from three different lines of transgenic mice were subjected to 24 h
organ culture and supernatants subsequently assayed by ELISA for
murine IL-1ra (mIL-1ra), as described. po0.001 relative to FVB line.
(b) Epidermal sheets from IL-1.2 (keratin-14–IL-1a transgenic) mice
were co-incubated with either a neutralizing antibody against mIL-1RI
or an irrelevant control antibody and supernatants subsequently as-
sayed for IL-1ra by ELISA. Data represent the mean and SEM values for
each treatment across three replicate experiments. po0.001.
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is stimulated following IL-1ra exposure in keratinocytes is
novel.
It is important to note that the effects observed in murine
epidermis relate only to extracellular IL-1 molecules. This
has several unexpected implications, most notably, that a
low level of pericellular IL-1 activity is present around nor-
mal keratinocytes. The lack of regulation of opposing IL-1
agonists and antagonists in epidermal homogenates noted
in our study strongly suggests that the important site for
constitutive IL-1a activity is extracellular, rather than intra-
cellular. Indeed, the release of IL-1a in significant quantities
is surprising in itself, as this molecule lacks a signal peptide
and the mechanism of its release has been the subject of
much speculation. Application of mechanical stress to hu-
man keratinocytes, however, has been shown to permit the
release of large quantities of IL-1a and IL-1ra in the absence
of cell death (Lee et al, 1997). Any role for IL-1b in this effect
is unlikely because this isoform is produced in negligible
quantities by murine keratinocytes (Ansel et al, 1988). Fur-
ther, any IL-1b that is synthesized remains in the bio-inac-
tive pro-form, as a result of deficient caspase-1 processing
in this cell type (Mizutani et al, 1991) and we found no
increase in the release of IL-1b in the epidermal sheets
derived from RA1 or RA10 mice (data not shown).
The release of significant quantities of IL-1ra from the
epidermal sheets of mice overexpressing IL-1a was un-
expected, given the absence of a leader sequence in icIL-1ra
isoforms. Although we cannot exclude a contribution from
bone marrow-derived cells, for example Langerhans cells, it
is most likely that the IL-1ra is keratinocyte-derived. Not
only did we observe a similar induction of IL-1ra by IL-1a in
our PAM212 cells, but cultured human keratinocytes have
been shown previously to release both IL-1a and icIL-1ra
into supernatants (Corradi et al, 1995). RT-PCR experiments
suggested that sIL-1ra accounted for this increase, al-
though it should be noted that very low levels of this tran-
script were found, relative to the intracellular variant.
Indeed, sIL-1ra mRNA was detected only weakly in
PAM212 keratinocytes by RT-PCR following treatment with
IL-1a (data not shown) and previous studies have found
similarly low levels of this isoform in murine skin following
lipopolysaccharide administration (Gabay et al, 1997). As
the increase in total IL-1ra release in IL-1.2 epidermal
sheets was more than 8-fold, it is likely that both isoforms
contributed to this effect. Irrespective of the cellular source,
it is clear that, both in isolated keratinocytes in culture and
Figure 4
Counter-regulation of interleukin (IL)-1a and IL-1ra is mediated
through the type I IL-1 receptor (IL-1R1) in keratinocytes in vitro. (a)
PAM212 cells were incubated with or without IL-1 receptor antagonist
(IL-1ra) (3 ng per mL) in the presence or absence of antibodies against
either murine IL-1R1 (mIL-1RI) or mIL-1RII (10 mg per mL) for 24 h at
371C prior to ELISA analysis for IL-1a. (b) PAM212 cells were incubated
under the same conditions as (a) in the presence of IL-1a (3 ng per mL)
and assayed for IL-1ra. Data represent the mean and SEM values for
each treatment across three replicate experiments.
Figure5
Keratinocytes increase release of interleukin (IL)-1a following ex-
posure to soluble type 1 IL-1 receptor (IL-1R). PAM212 cells were
incubated overnight at 371C in the presence or absence of increasing
concentrations of recombinant soluble IL-1 receptor type I (sIL-1RI) and
supernatants were subsequently analyzed by ELISA for IL-1a. Data
represent the mean and SEM values for each treatment across three
replicate experiments.
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in intact epidermis, there is tight regulation of IL-1a by IL-1ra
and vice versa.
The observed regulation of keratinocyte IL-1a release by
IL-1ra would not be predicted from the known functions of
these molecules and underscores the importance of IL-1
homeostasis in the normal cutaneous environment. For a
putative IL-1 homeostatic mechanism to function, it is likely
that keratinocytes signal an excess or deficit of extracellular
IL-1 molecules through the type-1 IL-1 receptor, and our
data indicate that this is indeed the case. We hypothesize
that low-level ligation of type-1 IL-1 receptor occurs in nor-
mal keratinocytes both in vitro and in vivo. Should there be
perturbation of this low-level receptor occupancy, either by
the presence of excess receptor agonists or antagonists,
keratinocytes respond by releasing the opposing molecule
(Fig 6). It should be stressed that this model does not sug-
gest a novel signaling role for IL-1ra, only that IL-1RI oc-
cupancy by IL-1ra molecules blocks the signal transduced
by IL-1a, which has the effect of reversing the induction of
IL-1ra and repression of IL-1a induced by agonist ligand
binding.
The physiologic role of constitutive cutaneous release of
IL-1a is uncertain. One hypothesis is that keratinocyte-de-
rived IL-1 is required for the production of other molecules
involved in tissue homeostasis such as keratinocyte growth
factor and granulocyte macrophage colony stimulating fac-
tor from dermal fibroblasts (Szabowski et al, 2000). Alter-
natively, it may simply act to maintain a ‘‘tick-over’’ of
the cutaneous IL-1 system, ensuring that keratinocytes are
primed for IL-1 release in case of injury or other noxious
stimulus.
If such a homeostatic role exists, IL-1a and IL-1ra are
unlikely to be the sole players in the pathway as neither IL-
1a nor IL-1ra knockout mice show any gross cutaneous
abnormalities (Horai et al, 1998; Nicklin et al, 2000), al-
though deletion of the IL-1ra gene specifically on a BALB/c
background has been demonstrated recently to induce cu-
taneous inflammation on ear pinnae (Shepherd et al, 2004).
Six new members of the IL-1 superfamily have been cloned
(Dunn et al, 2001) and, although none has been reported to
exhibit high-affinity binding to cell surface IL-1RI, three
members (IL-1F6, IL-1F8, and IL-1F9) have been shown re-
cently to activate the pathway leading to nuclear factor kB
translocation following binding to an IL-1 receptor homolog
(Towne et al, 2004). Whether these new molecules influence
the delicate balance of IL-1 in the epidermis awaits further
investigation.
The data presented here represent a description of mu-
tual counter-regulation of IL-1 receptor ligands in keratin-
ocytes and underscore the necessity for tight control of this
cytokine system in the extracellular microenvironment
around epidermal keratinocytes. Our data indicating that
IL-1ra can induce a significant release of IL-1a in keratin-
ocytes may explain the cutaneous inflammatory response
that follows therapeutic administration of IL-1ra (Bresnihan,
1999) and illustrate the importance of fully understanding
the biology of the IL-1 system in the cutaneous micro-
environment.
Materials and Methods
Reagents PAM212 keratinocytes were a gift from Dr Stuart Yuspa
(NIH, Bethesda, Maryland). rmIL-1a, mIL-1ra, and goat anti-mouse
IL-1ra antibody were purchased from R&D Systems (Abingdon,
UK). Anti-CD45 antibody was purchased from Calbiochem (Not-
tingham, UK). Recombinant human sIL-1RI was a gift from Dr John
Sims (Amgen Corp., Seattle, Washington). The monoclonal
antibodies against mIL-1RI (35F5) and mIL-1RII (4E2) were kind
gifts from Dr Richard Chizzonite (Hoffman-La Roche, Nutley,
New Jersey).
Animals Transgenic mice used in these studies overexpressing
IL-1a (IL-1.2) have been described previously (Groves et al, 1995b).
To generate mice that overexpress IL-1ra in basal epidermis, cDNA
encoding the secreted form of mIL-1ra (a gift from Dr Alexander
Whitehead, University of Pennsylvania School of Medicine, Phila-
delphia, Pennsylvania; (Zahedi et al, 1991)) was cloned by blunt-
end ligation into the BamH1 site of the K14-hGH vector as pre-
viously described (Groves et al, 1995b). Transgenic mice were
generated in the FVB strain by pronuclear microinjection of the
K14–IL-1ra-hGH construct and two founder lines were identified by
Southern blot analysis, designated RA1 and RA10. Both lines
passed the transgene in a Mendelian fashion and their skin was
both grossly and histologically normal.
Eight- to 12-wk-old mice were used in all experiments, which
were carried out under the provisions of the Animals (Scientific
Procedures) Act, 1986 (UK).
Culture of PAM212 cells PAM212 murine keratinocytes were
maintained in RPMI 1640 medium supplemented with 10% new-
born calf serum, glutamine (2 mM), penicillin (100 U per mL),
streptomycin (100 mg per mL), and HEPES buffer (10 mM) (all re-
agents from Invitrogen, Paisley, UK). Cells were incubated at 371C
in a humidified atmosphere with 5% CO2. Confluent layers of
PAM212 cells in 48-well plates were incubated in triplicate with
increasing concentrations of IL-1a, IL-1ra, or sIL-1RI in a total vol-
ume of 0.5 mL per well in the presence or absence of anti-IL-1R
antibodies at a final concentration of 10 mg per mL for 24 h at 371C.
Subsequently, supernatants were collected, cleared by centrifu-
gation, and stored at 201C prior to ELISA analysis. For cell vi-
ability experiments, supernatant LDH levels were assessed using a
kit (Sigma-Aldrich, Gillingham, UK), according to the manufactur-
er’s instructions.
Preparation of epidermal homogenates Mouse ears were re-
moved and split into dorsal and ventral halves prior to incubation at
Figure 6
Schematic illustration of the homeostatic mechanism involved in
maintaining extracellular interleukin (IL)-1 activity in murine kera-
tinocytes.
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371C for 60 min in the presence of dispase I (2.5 U per mL in
phosphate-buffered saline (PBS); Roche, Lewes, UK). Epidermis
was separated from the dermis and washed thoroughly in PBS.
Epidermal sheets were then homogenized in 500 mL of extraction
buffer (50 mM Tris base, 150 mM NaCl) using a motorized mixer for
90 s. Homogenates were cleared by centrifugation, and stored at
201C. The total protein content was assessed using a modified
Bradford assay, according to the manufacturer’s instructions
(Sigma).
Organ culture of epidermal sheets Epidermal sheets prepared
by dispase separation as described above were placed in dupli-
cate into wells of a 24-well plate with 1 mL of RPMI 1640 medium
(Invitrogen) and incubated for 24 h at 371C. Supernatants were
subsequently aspirated, clarified by centrifugation, and stored at-
201C. For neutralization studies, anti-IL-1RI (35F5) or anti-IL-1ra
antibody were added to the culture medium at a final concentration
of 10 mg per mL at the onset of incubation. An isotype-matched,
irrelevant control antibody was used at the same concentration in
all experiments.
ELISA For the measurement of total mIL-1ra protein, an ELISA
was developed using antisera raised against rat IL-1ra protein.
Ninety-six-well plates (‘‘Maxisorp’’, NUNC, Roskilde, Denmark)
were coated with a polyclonal sheep anti-rat IL-1ra antibody at 2
mg per mL in bicarbonate coating buffer (0.1 M NaHCO3, 0.1 M
NaCl, pH 8.2) overnight at 41C. Non-specific binding sites were
blocked with 1% bovine serum albumin (Sigma) for 1 h at room
temperature. Samples or standards prepared from rmIL-1ra (R&D
Systems) were added at 100 mL per well and incubated for 2 h at
room temperature. Following thorough washing (wash buffer; 0.5M
NaCl, 2.5 mM NaH2PO4, 7.5 mM Na2HPO4, 0.1% vol/vol Tween
20), 100 mL of biotinylated polyclonal sheep anti-rat IL-1ra antibody
(1:1000 dilution in wash buffer) was added to each well and incu-
bated for 1 h at room temperature. Detection was achieved with
100 mL avidin–HRP (1:5000 dilution in wash buffer; Dako Cytoma-
tion, Ely, UK) for 30 min, followed by addition of 100 mL of substrate
solution (1 OPD tablet (Sigma) in 10 mL substrate buffer (34.7 mM
citric acid, 66.7 mM Na2HPO4) þ 2 mL H2O2) for 20 min and ter-
mination with 150 mL 1M H2SO4 prior to measurement of absorb-
ance at 490 nm. The IL-1ra ELISA was sensitive to 50 pg per mL
and did not distinguish between secreted and intracellular iso-
forms. IL-1ra concentrations obtained from the ELISA were nor-
malized to total protein content in each sample for comparison.
mIL-1a was assessed using a similar protocol, using a poly-
clonal sheep anti-mouse IL-1a antibody at 0.5 mg per mL for coat-
ing and a biotinylated polyclonal sheep anti-mouse IL-1a antibody
at 1:1000 dilution in wash buffer as a secondary antibody. Stand-
ards were prepared from rmIL-1a (R&D Systems) and the IL-1a
ELISA was sensitive to 30 pg per mL. IL-1a and IL-1b at concen-
trations up to 1 mg per mL were not detected in the ELISA for
mouse IL-1ra, and IL-1b and IL-1ra at concentrations up to 1 mg
per mL were not detected in the ELISA for mouse IL-1a.
RT-PCR For the measurement of isoform-specific IL-1ra, whole
ears were harvested and snap-frozen in liquid nitrogen, prior to
total RNA extraction using 3 mL Trizol (Invitrogen) per ear pair,
according to the manufacturer’s instructions. Reverse transcription
and PCR were performed as described elsewhere (Mee et al, 2000)
using murine-specific primers directed against hypoxanthine phos-
phoribosyltransferase (sense: GCTTCCTCCTCAGACCGCTTTTT,
antisense: AGGCTTTGTATTTGGCTTTTCCAGT; 601C annealing
temperature, 30 s extension time, 24 cycles), sIL-1ra (sense:
CCTCGGGATGGAAATCTG, antisense: CTGGTTGTTTCTCAGG-
TAAAAGG; 551C annealing temperature, 30 s extension time, 35
cycles), and icIL-1ra (sense: GCTCCTTTATACACAGCAAGTCTCT,
antisense: as sIL-1ra; 551C annealing temperature, 30 s extension
time, 30 cycles). Following electrophoresis, gels were scanned and
analysis was performed on a Macintosh computer using the public
domain NIH Image program (http://rsb.info.nih.gov/nih-image/).
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